DiaMedica Therapeutics Inc.

DMAC

CA25253X2077

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 16/07/2024 BST			5-day change	1st Jan Change
3.39 ^USD	-5.31%		+11.88%	+19.37%

07-01	DiaMedica Therapeutics Inc. announced that it has received $11.8 million in funding	CI
06-27	Transcript : DiaMedica Therapeutics Inc. - Special Call

DiaMedica Therapeutics Inc.(TSXV:DMA) dropped from S&P/TSX Venture Composite Index

January 21, 2019 at 05:00 am

Latest news about DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. announced that it has received $11.8 million in funding	06-30	CI
Transcript : DiaMedica Therapeutics Inc. - Special Call	06-27
DiaMedica Therapeutics Inc. Plans to Expand Its Clinical Trials into Preeclampsia	06-26	CI
DiaMedica Therapeutics Inc. announced that it expects to receive $11.8 million in funding	06-24	CI
DiaMedica Therapeutics Inc. Elects Rick Pauls as Director	05-23	CI
Transcript : DiaMedica Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
DiaMedica Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	04-17	MT
DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke	04-17	CI
DiaMedica Therapeutics Inc. Announces Executive Changes	04-10	CI
DiaMedica Therapeutics Files $100 Million Mixed Shelf	03-21	MT
Craig Hallum Cuts DiaMedica Therapeutics Price Target to $8 From $11, Maintains Buy Rating	03-21	MT
Oppenheimer Trims DiaMedica Therapeutics Price Target to $6 From $7, Maintains Outperform Rating	03-21	MT
Transcript : DiaMedica Therapeutics Inc., 2023 Earnings Call, Mar 20, 2024	03-20
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer	01-22	MT
DiaMedica Therapeutics Inc. Appoints Dr. Lorianne Masuoka as Chief Medical Officer	01-22	CI
Transcript : DiaMedica Therapeutics Inc., Q3 2023 Earnings Call, Nov 14, 2023	11-14
DiaMedica Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Top Premarket Gainers	25/10/23	MT
DiaMedica Therapeutics Inc. Announces the Appointment of Ambarish Shah as Chief Technology Officer	12/09/23	CI
Diamedica Therapeutics Inc. Announces Management Changes	05/09/23	CI
Transcript : DiaMedica Therapeutics Inc., Q2 2023 Earnings Call, Aug 15, 2023	15/08/23
DiaMedica Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
DiaMedica Therapeutics Inc. announced that it has received $37.4 million in funding	13/08/23	CI

Chart DiaMedica Therapeutics Inc.

Duration

Period

More charts

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

Sector

Biotechnology & Medical Research

Calendar

28/07/2024 - Investor Meeting - Key Opinion Leader

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.39 USD

Average target price

7 USD

Spread / Average Target

+106.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DIAMEDICA THERAPEUTICS INC.	+19.37%	153M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B

Bio Therapeutic Drugs